摘要:
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable faints thereof according to wherein all of the variables are defined herein.
摘要:
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein all of the variables are defined herein.
摘要:
Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.
摘要:
Compounds are provided which have the structure wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; D is —CH═ or C═O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C; and A, B, R1, R2, R2a, R4, R3, E, Z and Y are as defined herein, which compounds are useful in treating diabetes and related diseases.
摘要:
Compounds are provided having the formula (I) wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases.
摘要:
Substituted heterocyclic derivatives are provided which have the structure wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; D is —CH═ or C═O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4, X5 and X6 is N; and at least one of X2, X3, X4, X5 and X6 is C; A, B, R1, R2, R2a, R2b, R4, R3, E, Z and Y are as defined herein. In addition, a method is provided for treating diabetes, Type 2 diabetes, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, or atherosclerosis, wherein the substituted heterocyclic derivatives are administered in a therapeutically effective amount to a patient.
摘要翻译:提供了取代的杂环衍生物,其具有其中Z 1是(CH 2 CH 2)q或C-O的结构; Z 2是(CH 2)2或C-O; D是-CH-或C-O或(CH 2 CH 2)m,其中m是0,1,2或3; n = 0,1或2; p = 1或2; q = 0,1或2; Q是C或N; X是CH或N; X 2是C,N,O或S; X 3是C,N,O或S; X 4是C,N,O或S; X 5是C,N,O或S; X 6是C,N,O或S; 条件是X 2,X 3,X 4,X 5和X 3中的至少一个, 6是N; 和X 2,X 3,X 4,X 5和X 6中的至少一个 SUB>是C; A,B,R 1,R 2,R 2a,R 2b,R 4, R 3,R 3,E,Z和Y如本文所定义。 另外,提供了一种治疗糖尿病,2型糖尿病,胰岛素抵抗,高血糖症,高胰岛素血症,升高的脂肪酸或甘油血糖水平,高脂血症,肥胖症,高甘油三酯血症,综合征X或动脉粥样硬化的方法,其中给予取代的杂环衍生物 以治疗有效量给予患者。
摘要:
wherein Z1 is (CH2)q or C═O; Z2 is (CH2)p or C═O; D is —CH═ or C═O or (CH2)m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH2)x where x is 1 to 5, or A is (CH2)x1, where x1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH2)x2—O—(CH2)x3— where x2 is 0 to 5 and x3 is 0 to 5, provided that at least one of x2 and x3 is other than 0; B is a bond or is (CH2)x4 where x4 is 1 to 5; X is CH or N; X2 is C, N, O or S; X3 is C, N, O or S; X4 is C, N, O or S; X5 is C, N, O or S; X6 is C, N, O or S; provided that at least one of X2, X3, X4 X5 and X6 is N; and at least one of X2, X3, X4 X5 and X6 is C. R1 is H or alkyl; R2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R2a, R2b and R2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R3, E, Z and Y are as defined herein.
摘要:
Disclosed are a method and apparatus for processing physiological signals. The method is inclusive of steps of obtaining the physiological signals; grouping the physiological signals based on their sampling frequencies and/or generation mechanisms, so as to acquire grouping results; and compressing, based on the grouping results, each group of physiological signals.
摘要:
A mental health equipment data store may contain electronic records associated with mental health equipment identifiers. For each mental health equipment identifier, the data store may include a communication address and associated equipment parameters. A risk relationship data store may contain electronic records associated with parties having risk relationships with an enterprise. A back-end application computer server may associate a selected equipment identifier in the mental health equipment data store with a selected party having a risk relationship with the enterprise. The server may update the risk relationship data store with the selected equipment identifier and arrange to collect selected mental health data for the selected party in accordance with the communication address of the selected equipment identifier. The selected mental health data is input to a predictive model algorithm, and the server automatically executes a treatment workflow for the selected party based on an output of the algorithm.
摘要:
FIG. 1 is a first perspective view of a fishing rod holder showing my new design; FIG. 2 is a second perspective view thereof; FIG. 3 is a front view thereof; FIG. 4 is a back view thereof; FIG. 5 is a left side view thereof; FIG. 6 is a right side view thereof; FIG. 7 is a top view thereof; and, FIG. 8 is a bottom view thereof. The broken lines shown in the drawings depict portions of the fishing rod holder that form no part of the claimed design.